<DOC>
	<DOCNO>NCT03000374</DOCNO>
	<brief_summary>Patients rectal adenocarcinoma intermediate risk ( define magnetic resonance image [ MRI ] ) , without mutation KRAS , BRAF , NRAS PI3KCA , candidate preoperative treatment , receive preoperative Induction therapy 12 week panitumumab mFOLFOX-6 evaluate efficacy term pathologic complete response ( pCR )</brief_summary>
	<brief_title>Induction Therapy With Panitumumab + mFOLFOX-6 Rectal Cancer Quadruple Wild-type Mutation Before Surgery</brief_title>
	<detailed_description>Phase II , nonrandomized single-arm trial preoperative treatment mFOLFOX-6 panitumumab enrich population patient rectal adenocarcinoma intermediate risk , screen MRI , without mutation KRAS , BRAF , NRAS PI3K . All patient enrol study receive 12 week investigational product ( mFOLFOX-6 panitumumab ) every 14 day six cycle , unless unacceptable toxicity occur progression detect . After treatment , response evaluate diffusion-weighted MRI endoscopy . In absence disease progression , patient eligible R0 resection undergo total mesorectal excision ( TME ) . After surgery , patient receive mFOLFOX6 x 6 cycle . In case intolerance FOLFOX-panitumumab , disease progression ineligibility R0 resection , patient receive chemoradiotherapy capecitabine 825 mg/m2 every 12 hour concomitantly radiotherapy ( RT ) total dose 50.4 Gy . At end treatment , patient undergo TME 6 8 week end chemoradiotherapy . If patient withdraws consent refuse continue treatment , patient follow 24 month , enrollment last patient trial , progression occurs , order assess disease-free survival . If patient withdraws consent refuse continue participate study , follow-up evaluation must discontinue .</detailed_description>
	<mesh_term>Rectal Neoplasms</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>1 . Signed date informed consent form , willingness ability comply requirement protocol ; 2 . Men woman rectal cancer , age ≥ 18 &lt; 75 year ; 3 . Histologically documented adenocarcinoma rectum . All histologic type exclude . A minimum 4 biopsy rectal primary tumor must available , tumor representation &gt; 50 % sample . The sample send Vall d'Hebron Institute Oncology ( VHIO ) molecular determination . The 4 block 4 biopsy send include paraffin . 4 . Rectal cancer candidate R0 resection preservation rectal sphincter . 5 . Tumors follow characteristic highresolution thinslice ( 3 mm ) MRI : 1. mrT3 2 . Tumors middle third , define tumor inferior margin ≤ 12 cms anal verge plane elevator ( insertion elevator ) . 3 . Absence MRF invasion , define distance ≥ 1 mm tumor fascia ; 6 . Absence mutation KRAS ( mutation KRAS exon 2 [ codon 12/13 ] , exon 3 [ codon 59/61 ] exon 4 [ codon 117/146 ] , NRAS ( NRAS exon 2 [ codon 12/13 ] , exon 3 [ codon 59/61 ] exon 4 [ codon 117/146 ] ) , BRAF ( exon 15 [ codon 600 ] PI3KCA exons 9 20 7 . ECOG performance status ≤ 2 ; 8 . Hematological status : Neutrophils ( ANC ) ≥ 1.5 x 109/L ; Platelets ≥ 100 x 109/L ; Hemoglobin ≥ 9 g/dL ; 9 . Adequate renal function : serum creatinine &lt; 1.5 x upper limit normal ( ULN ) ; 10 . Adequate liver function : Serum bilirubin ≤ 1.5 x ULN , Alkaline phosphatase &lt; 5 x ULN , AST/ALT &lt; 3 x ULN ; 11 . Regular monitoring feasible ; 12 . In woman childbearing potential , negative serum pregnancy test within 1 week ( 7 day ) start study treatment ; 13 . Women must commit use reliable appropriate method contraception least three month end study treatment ( applicable ) . Men partner childbearing potential must agree use method contraception partner must use another contraceptive method duration trial . 1 . Mucinous adenocarcinoma . 2 . N2 lymph node involvement , define : 4 lymph node mesorectum show morphological sign metastatic involvement MRI . A lymph node consider malignant : 1 . Short axis &gt; 9 mm . 2 . Short axis 59 mm ≥2 follow criterion : Rounded appearance . ii Heterogeneous margin . iii Heterogeneous signal intensity . 3 . Axis &lt; 5 mm AND round shape AND heterogeneous margin AND heterogeneous signal intensity . 3 . Extramesorectal lymph node involvement : involve extramesorectal lymph node define lymph node obturator area short axis &gt; 10 mm , round shape heterogeneous signal . 4 . Prior treatment panitumumab cetuximab ; 5 . Preexisting permanent neuropathy ( grade ≥ 2 NCICTCAE ) ; 6 . Concomitant antitumor treatment foreseen protocol ( e.g. , chemotherapy , target molecular therapy , immunotherapy ) ; 7 . Treatment investigational medicinal product within 28 day prior study entry ; 8 . Other simultaneous prior malignancy , except : ) properly treat uterine cervix carcinoma situ , ii ) basal squamous cell skin carcinoma , iii ) cancer complete remission period &gt; 5 year ; 9 . Evidence metastatic disease additional study physical examination ; 10 . Any severe uncontrolled nonmalignant disease , major surgery traumatic injury last 28 day ; 11 . Pregnant breastfeeding woman ; 12 . Patients know allergy excipient investigational product ; 13 . Clinically significant cardiovascular disease , include myocardial infarction , unstable angina , symptomatic congestive heart failure cardiac arrhythmia year randomization study . 14 . Intestinal occlusion : In case intestinal occlusion , patient may enrol study perform derivative stoma . 15 . Interstitial Lung Disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>74 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>